RNF25 promotes gefitinib resistance in EGFR-mutant NSCLC cells by inducing NF-κB-mediated ERK reactivation

Non-small cell lung cancer (NSCLC) patients with EGFR mutations initially respond well to EGFR tyrosine kinase inhibitors (TKIs) but eventually exhibit acquired or innate resistance to the therapies typically due to gene mutations, such as EGFR T790M mutation or a second mutation in the downstream p...

Descripción completa

Detalles Bibliográficos
Autores principales: Cho, Jung Hee, You, Yeon-Mi, Yeom, Y I, Lee, Dong Chul, Kim, Bo-Kyung, Won, Misun, Cho, Byoung Chul, Kang, Minho, Park, Seulki, Yang, Suk-Jin, Kim, Jang Seong, Kim, Jung-Ae, Park, Kyung Chan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5964247/
https://www.ncbi.nlm.nih.gov/pubmed/29789542
http://dx.doi.org/10.1038/s41419-018-0651-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5964247/
https://www.ncbi.nlm.nih.gov/pubmed/29789542
http://dx.doi.org/10.1038/s41419-018-0651-5

Ejemplares similares